Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4ONW5)

Drug Name
Baricitinib Drug Info
Synonyms Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [2]
Cross-matching ID
PubChem CID
44205240
ChEBI ID
CHEBI:95341
CAS Number
CAS 1187594-09-7
TTD Drug ID
DM4ONW5
VARIDT Drug ID
DR00322
INTEDE Drug ID
DR2502
ACDINA Drug ID
D00859

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Modulator [3]
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Modulator [3]
Tyrosine-protein kinase (PTK) TTJSQEF NOUNIPROTAC Inhibitor [1]
HUMAN adaptor-associated kinase 1 (AAK1) TTN9A16 AAK1_HUMAN Inhibitor [4]
HUMAN cyclin G-associated kinase (GAK) TT0AGBL GAK_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID Highest Status REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Approved [5]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Approved [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Approved [7]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Janus kinase 2 (JAK-2) DTT JAK2 4.957 5.257 4.986 4.784
Janus kinase 1 (JAK-1) DTT JAK1 8.621 9.012 9.168 8.535
P-glycoprotein 1 (ABCB1) DTP P-GP 7.009 6.988 7.442 8.135
Breast cancer resistance protein (ABCG2) DTP BCRP 6.732 7.513 6.326 9.277
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Rheumatoid arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-glycoprotein 1 (ABCB1) DTP P-GP 7.23E-01 -8.20E-02 -3.22E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 9.93E-01 -1.09E-01 -5.77E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 ClinicalTrials.gov (NCT04345289) Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. U.S. National Institutes of Health.
3 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
4 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31.
5 Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
6 Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519.
7 FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration.